双核素FDG和FET正电子发射断层扫描诊断胶质瘤的临床价值

doi:10.19854/j.cnki.1008-2425.2025.05.0001

摘要/Abstract

摘要： 目的分析双核素2-[¹⁸F]-氟-2-脱氧-D-葡萄糖(¹⁸F-FDG)和O-(2-[¹⁸F]-氟乙基)-L-酪氨酸(¹⁸F-FET)正电子发射断层扫描在胶质瘤中的临床价值。方法本研究纳入2023年7月至2024年9月病理诊断胶质瘤的患者。术前进行¹⁸F-FDG和¹⁸F-FET正电子发射断层扫描。双核素标准化摄取值(standardized uptake value,SUV)参数包括平均值(SUVmean)、最大值(SUVmax)和最小值(SUVmin)。根据摄取值,摄取模式分为两种类型:阳性摄取,SUVmean大于正常脑组织;阴性摄取,SUVmean不高于正常脑组织。通过Pearson相关性分析FET和FDG的SUV与肿瘤增殖标志物Ki-67及P53蛋白表达之间的相关性。结果 18例病理诊断为胶质瘤患者术前进行双核素FDG和FET检查。所有胶质瘤均表现出FET阳性摄取。双核素摄取模式:FET阳性摄取/FDG阳性摄取(12例,66.7%),FET阳性摄取/FDG阴性摄取(6例,33.3%)。3例(16.7%)双核素诊断与病理结果完全一致,15例(83.3%)不完全一致。双核素SUV与Ki-67和P53蛋白表达无相关性(P>0.05)。结论双核素正电子发射断层扫描在胶质瘤辅助诊断中具有重要临床应用价值。FDG和FET双阳性摄取是最常见的摄取模式。相较于单一FDG检查,双核素FDG和FET的摄取模式为胶质瘤诊断提供了更多的线索。

关键词: 双核素, 正电子发射断层扫描, FDG, FET, 标准化摄取值, 胶质瘤

Abstract: Objective To analyze the clinical value of dual-nuclide 2-[¹⁸F]-fluoro-2-deoxy-D-glucose (¹⁸F-FDG) and O-(2-[¹⁸F]-fluoroethyl)-L-tyrosine (¹⁸F-FET) positron emission tomography in gliomas. Methods This study included patients diagnosed with gliomas pathologically from July 2023 to September 2024.Preoperative ¹⁸F-FDG and ¹⁸F-FET positron emission tomography scans were performed.The parameters of the dual-nuclide standardized uptake value (SUV) include the mean (SUVmean),maximum (SUVmax),and minimum (SUVmin) values.Based on the uptake values,the uptake patterns are categorized into two types:positive uptake,where SUVmean exceeds that of normal brain tissue,and negative uptake,where SUVmean does not surpass that of normal brain tissue.The correlation between the SUVs of FET and FDG with the tumor proliferation markers Ki-67 and P53 protein expression was evaluated using Pearson correlation analysis. Results Eighteen patients with pathologically confirmed gliomas underwent dual-nuclide FDG and FET imaging prior to surgery.All gliomas demonstrated positive FET uptake.Dual-nuclide uptake patterns were as follows:FET positive uptake/FDG positive uptake (12 cases,66.7%),FET positive uptake/FDG negative uptake (6 cases,33.3%).Three cases (16.7%) showed complete concordance between dual-radionuclide diagnosis and pathological findings,while 15 cases (83.3%) exhibited partial concordance.The correlation between SUV values obtained from dual-nuclide imaging and the expression levels of Ki-67 and P53 proteins was not statistically significant (P>0.05). Conclusion Dual-nuclide positron emission tomography holds significant clinical utility in the auxiliary diagnosis of gliomas.The most common uptake pattern observed was dual-positive uptake for both FDG and FET.Compared to single FDG imaging,the dual-nuclide uptake pattern of FDG and FET provides more diagnostic clues for glioma.

Key words: Dual-nuclide, Positron emission tomography, 2-[¹⁸F]-fluoro-2-deoxy-D-glucose, O-(2-[¹⁸F]-fluoroethyl)-L-tyrosine, Standardized uptake value, Glioma

中图分类号:

R739.4

任宇涛, 孟强, 刘永, 李焕发, 张华. 双核素FDG和FET正电子发射断层扫描诊断胶质瘤的临床价值[J]. 立体定向和功能性神经外科杂志, 2025, 38(5): 257-262.

Ren yutao, Meng Qiang, Liu yong, Li huanfa, Zhang hua. Clinical Value of Dual-nuclide FDG and FET Positron Emission Tomography in the Diagnosis of Gliomas Department of Neurosurgery.[J]. Chinese Journal of Stereotactic and Functional Neurosurgery, 2025, 38(5): 257-262.

参考文献

[1] Zhang GS,Li JH,Hui XH.Use of ¹⁸F-FDG-PET/CT in differential diagnosis of primary central nervous system lymphoma and high-grade gliomas:A meta-analysis[J]. Front,2022,13:935459.
[2] Wong TZ,Der Westhuizen GJ,Coleman RE.Positron emission tomography imaging of brain tumors[J].Neuroimaging Clin N Am,2002,12(4):615~626.
[3] Zhao C,Zhang Y,Wang J.A meta-analysis on the diagnostic performance of ¹⁸F-FDG and 11C-methionine PET for differentiating brain tumors[J] Am J Neuroradiol,2014,35(6):1058~1065.
[4] Piccardo A,Garibotto V,Castello A.Positron emission tomography from FDG to amino acid tracers[M]//Advanced Imaging and Therapy in Neuro-Oncology. Cham:Springer Nature Switzerland,2024,3:31~57.
[5] Singnurkar A,Poon R,Detsky J,¹⁸F-FET-PET imaging in high-grade gliomas and brain metastases:a systematic review and meta-analysis[J].J Neuro Oncol,2023,161(1):1~12.
[6] Häfliger P,Charles RP.The L-type amino acid transporter LAT1-an emerging target in cancer[J].Int J Mol Sci,2019,20(10):2428.
[7] Dunet V,Pomoni A,Hottinger A,et al.Performance of 18F-FET versus ¹⁸F-FDG-PET for the diagnosis and grading of brain tumors:systematic review and meta-analysis[J].Neuro Oncol,2016,18(3):426~434.
[8] Krebs S,Mauguen A,Yildirim O,et al.Prognostic value of [¹⁸F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies[J].Eur J Nucl Med Mol Imaging,2021,48(12):3940~3950.
[9] Plotkin M,Blechschmidt C,Auf G,et al.Comparison of F-18 FET-PET with F-¹⁸ FDG-PET for biopsy planning of non-contrast-enhancing gliomas[J].Eur Radiol,2010,20(10):2496~2502.
[10] Pauleit D,Stoffels G,Bachofner A,et al.Comparison of 18F-FET and ¹⁸F-FDG PET in brain tumors[J].Nucl Med Biol,2009,36(7) 779~787.
[11] Louis DN,Perry A,Wesseling P,et al.The 2021 WHO classification of tumors of the central nervous system:a summary[J]. Neuro Oncol,2021,23(8):1231~1251.
[12] Albert NL,Weller M,Suchorska B,et al.Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas[J].Neuro-oncology,2016,18(9):1199~1208.
[13] Brendle C,Maier C,Bender B,et al.Impact of 18F-FET PET/MRI on clinical management of brain tumor patients[J]. J Nucl Med,2022,63(4):522~527.
[14] Cao X,Tan D,Liu Z,et al.Differentiating solitary brain metastases from glioblastoma by radiomics features derived from MRI and ¹⁸F-FDG-PET and the combined application of multiple models[J].2022,Sci Rep,2022,12(1):5722.
[15] Quartuccio N,Laudicella R,Vento A,et al.The additional value of ¹⁸F-FDG PET and MRI in patients with glioma:a review of the literature from 2015 to 2020[J].Diagnostics,2020,10(6):357.
[16] Shaw TB,Jeffree RL,Thomas P,et al.Diagnostic performance of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of glioma[J].J Med Imag Rad Onc,2019,63(5):650~656.
[17] Olivero WC,Dulebohn SC,Lister JR,The use of PET in evaluating patients with primary brain tumours:is it useful[J].J Neurol Neurosurg Psychiatry 1995,58(2):250~252.
[18] Chen W,Clinical applications of PET in brain tumors[J]. J Nucl Med,2007,48(9):1468~1481.
[19] Jager PL,Vaalburg W,Pruim J,et al.Radiolabeled amino acids:basic aspects and clinical applications in oncology,Journal of nuclear medicine:official publication[J]. Society Nucl Med,2001,42(3):432~445.
[20] Deykin D,Balko C,Isselbacher KJ. Sugar and amino acid transport by cells in culture-differences between normal and malignant cells[J].N Engl J Med,1972,286(17):929~933.
[21] Weber WA,Wester HJ,Grosu AL,et al. O-(2-[¹⁸F]Fluoroethyl)-l-tyrosine and l-[methyl-11C]methionine uptake in brain tumours:initial results of a comparative study[J]. Eur J Nucl Med,2000,27(5):542~549.
[22] Becherer A,Karanikas G,SzabóM,et al. Brain tumour imaging with PET:a comparison between 18Ffluorodopa and 11C methionine[J]. Eur J Nucl Med Mol Imag,2003,30(11):1561~1567.
[23] Rapp M,Heinzel A,Galldiks N,et al.Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma[J].J Nucl Med,2013,54(2):229~235.